 | |
| Company type | Public |
|---|---|
| SIX: BSLN | |
| Industry | Pharmaceutical industry |
| Founded | 2000 |
| Headquarters | Allschwil, Switzerland |
Key people | David Veitch (Chief Executive Officer)[1] Domenico Scala (Chairman of the Board][2] |
| Products | Isavuconazole, Ceftobiprole |
| Revenue | CHF 157.6 million (2023)[3] |
Number of employees | 147 (2023)[3] |
| Website | www |
Basilea Pharmaceutica is a biopharmaceutical company based in Allschwil near Basel, Switzerland.[4] Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004.[5] The company's subsidiary is Basilea Pharmaceutica International AG, Allschwil, which is also based in Allschwil, Switzerland, and in which the company's operating activities are bundled.[6]
- ^ "David Veitch: Chief Executive Officer, Basilea Pharmaceutica AG". Bloomberg. 2023. Retrieved 2024-07-21.
- ^ "Domenico Scala wird Davidoff-Präsident: Vom Fifa-Reformer zum Zigarren-Boss". Blick. 2018-09-12. Retrieved 2024-07-21.
- ^ a b Full-Year Report 2023, published in Public Now, 12 February 2024, retrieved 12 April 2024.
- ^ "US pays Basel pharma firm to develop new antibiotic". SWI swissinfo.ch. 2016-04-20. Retrieved 2024-07-20.
- ^ "Basilea nähert sich der Gewinnzone". Handelszeitung. 27 february 2018.
- ^ "Firmenprofil: Basilea Pharmaceutica International AG, Allschwil". Dun & Bradstreet. 2 January 2024.